UK regulator approves new oral weight-loss pill for obesity and type 2 diabetes
The UK's Medicines and Healthcare products Regulatory Agency has approved Eli Lilly's oral pill Foundayo for treating obesity and type 2 diabetes. The approval is national in scope. The drug is not yet automatically available on the NHS and will initially be available through private prescription. Potential side effects include nausea and diarrhoea, and long-term real-world efficacy has not yet been established.
Why it matters
This provides a new oral treatment option for obesity and type 2 diabetes, conditions that affect millions of people and have limited effective medication choices.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news